BPC-157 Blocks Amphetamine's Effects and Prevents Drug Sensitivity Buildup
The gut peptide BPC-157 blocked amphetamine-induced repetitive behaviors in rats and prevented the development of heightened drug sensitivity caused by haloperidol.
Quick Facts
What This Study Found
BPC-157 blocked acute amphetamine-induced stereotypy and prevented haloperidol-induced dopamine supersensitivity to amphetamine, without affecting normal baseline behavior.
Key Numbers
How They Did This
Animal study in rats. BPC-157 was administered alongside amphetamine to measure acute effects on stereotypy, and during chronic haloperidol treatment to assess prevention of dopamine receptor supersensitivity.
Why This Research Matters
BPC-157's ability to normalize disrupted dopamine signaling without sedating effects suggests it could have potential in treating conditions involving dopamine dysregulation, such as substance abuse or movement disorders.
The Bigger Picture
Dopamine system disruption underlies many neurological and psychiatric conditions. A peptide that can selectively normalize dopamine signaling without suppressing normal function represents a fundamentally different approach from current medications that broadly dampen or boost dopamine.
What This Study Doesn't Tell Us
Animal study only. The exact mechanism by which BPC-157 interacts with the dopamine system was not determined. Doses and clinical translation to humans remain unknown.
Questions This Raises
- ?What is BPC-157's exact mechanism of action on dopamine receptors?
- ?Could BPC-157 help prevent tardive dyskinesia in patients taking antipsychotics?
- ?Does BPC-157 affect other neurotransmitter systems beyond dopamine?
Trust & Context
- Key Stat:
- Dual action BPC-157 both blocked acute amphetamine effects and prevented chronic haloperidol-induced supersensitivity
- Evidence Grade:
- Moderate evidence from a controlled animal study showing clear behavioral effects, but mechanism undefined and no human data.
- Study Age:
- Published in 1998. BPC-157's dopamine-related effects have been explored further in subsequent animal studies.
- Original Title:
- A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.
- Published In:
- Biological psychiatry, 43(7), 511-9 (1998)
- Authors:
- Jelovac, N(9), Sikirić, P(10), Rucman, R(29), Petek, M, Perović, D, Konjevoda, P, Marović, A, Seiwerth, S, Grabarević, Z, Sumajstorcić, J, Dodig, G, Perić, J
- Database ID:
- RPEP-00465
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a peptide derived from a protein found in human gastric juice. It has been studied for wound healing, gut protection, and increasingly for its effects on the nervous system.
What does this mean for people taking antipsychotics?
This early animal study suggests BPC-157 might help prevent the dopamine supersensitivity that causes side effects like tardive dyskinesia from long-term antipsychotic use. However, this has not been tested in humans and should not guide clinical decisions.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00465APA
Jelovac, N; Sikirić, P; Rucman, R; Petek, M; Perović, D; Konjevoda, P; Marović, A; Seiwerth, S; Grabarević, Z; Sumajstorcić, J; Dodig, G; Perić, J. (1998). A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.. Biological psychiatry, 43(7), 511-9.
MLA
Jelovac, N, et al. "A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.." Biological psychiatry, 1998.
RethinkPeptides
RethinkPeptides Research Database. "A novel pentadecapeptide, BPC 157, blocks the stereotypy pro..." RPEP-00465. Retrieved from https://rethinkpeptides.com/research/jelovac-1998-a-novel-pentadecapeptide-bpc
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.